News for Astellas Pharma Inc. (ALPMY)

Astellas Pharma (ALPMY) partners with KISED to support Korean drug-discovery startups. The program includes access to Astellas' SakuLabâ„¢-Tsukuba facil

A Chinese court sentenced a Japanese national to prison for espionage, in a verdict that threatens to test ties anew between Asia’s two largest economies.

XTANDI® plus leuprolide significantly improves overall survival in non-metastatic hormone-sensitive prostate cancer. The Phase 3 EMBARK study shows a m

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the ov

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

PR NewswireTOKYO and SUZHOU, China, May 29, 2025 - Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and T

Astellas Pharma enters a licensing deal with Evopoint Biosciences valued at $1.54 billion plus royalties. XNW27011 targets CLDN18.2-expressing solid tum

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

PR NewswireTOKYO and NEW YORK, May 22, 2025 Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation th

PR NewswireTOKYO, May 19, 2025 16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolioTOKYO, May 19, 20

Astellas to present 16 abstracts at the 2025 ASCO Annual Meeting, focusing on long-term survival data for XTANDI (enzalutamide) and PADCEV (enfortumab vedo

Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

PR NewswireTOKYO, May 1, 2025 ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAYâ„

Astellas Pharma set to present nine new abstracts on geographic atrophy (GA) at ARVO and RWC 2025. Key presentations will focus on the GATHER Phase 3 st

Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albe

Apr 25, 2025 / 08:00AM GMTPresentationApr 25, 2025 / 08:00AM GMT =====================Corporate Participants===================== * Hiromitsu Ikeda Aste

Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.